Does the media favor ALXO or COLL?

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.94 beat Collegium Pharmaceutical's score of 0.75 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Collegium Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ORIC or ALXO?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is ORIC or ALXO more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% ALX Oncology N/A -124.06% -85.57%

Does the media refer more to ORIC or ALXO?

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than ALX Oncology. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.94 beat Oric Pharmaceuticals' score of 0.43 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, CGEM or ALXO?

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is CGEM or ALXO more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% ALX Oncology N/A -124.06% -85.57%

Does the media favor CGEM or ALXO?

In the previous week, Cullinan Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.94 beat Cullinan Therapeutics' score of 0.34 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is PURR or ALXO more profitable?

Hyperliquid Strategies' return on equity of -56.04% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Hyperliquid Strategies N/A -56.04% -52.22% ALX Oncology N/A -124.06% -85.57%

Is ALXO or BIOA more profitable?

ALX Oncology has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% BioAge Labs -871.75% -29.40% -27.26%

Does the media refer more to ALXO or BIOA?

In the previous week, BioAge Labs had 4 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for BioAge Labs and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.94 beat BioAge Labs' score of 0.57 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioAge Labs 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ALX Oncology (ALXO) Competitors

$1.92 -0.18 (-8.57%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 0.00 (-0.26%)

As of 07:34 PM Eastern

Compare

ALXO vs. COLL, ORIC, CGEM, PURR, and BIOA

Should you buy ALX Oncology stock or one of its competitors? MarketBeat compares ALX Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALX Oncology include Collegium Pharmaceutical (COLL), Oric Pharmaceuticals (ORIC), Cullinan Therapeutics (CGEM), Hyperliquid Strategies (PURR), and BioAge Labs (BIOA). These companies are all part of the "pharmaceutical products" industry.

How does ALX Oncology compare to Collegium Pharmaceutical?

ALX Oncology (NASDAQ:ALXO) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.94 beat Collegium Pharmaceutical's score of 0.75 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Collegium Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

ALX Oncology currently has a consensus target price of $4.60, indicating a potential upside of 139.58%. Collegium Pharmaceutical has a consensus target price of $57.50, indicating a potential upside of 61.79%. Given ALX Oncology's higher possible upside, analysts plainly believe ALX Oncology is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17

Collegium Pharmaceutical has a net margin of 9.41% compared to ALX Oncology's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Collegium Pharmaceutical has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Collegium Pharmaceutical	$780.57M	1.48	$62.87M	$2.04	17.42

98.0% of ALX Oncology shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Collegium Pharmaceutical beats ALX Oncology on 11 of the 16 factors compared between the two stocks.

How does ALX Oncology compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Oric Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

In the previous week, Oric Pharmaceuticals had 6 more articles in the media than ALX Oncology. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.94 beat Oric Pharmaceuticals' score of 0.43 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Oric Pharmaceuticals' return on equity of -35.33% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
ALX Oncology	N/A	-124.06%	-85.57%

Oric Pharmaceuticals presently has a consensus target price of $19.27, indicating a potential upside of 84.96%. ALX Oncology has a consensus target price of $4.60, indicating a potential upside of 139.58%. Given ALX Oncology's higher probable upside, analysts clearly believe ALX Oncology is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Oric Pharmaceuticals beats ALX Oncology on 7 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

In the previous week, Cullinan Therapeutics had 2 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for Cullinan Therapeutics and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.94 beat Cullinan Therapeutics' score of 0.34 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 21.0% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cullinan Therapeutics' return on equity of -51.45% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
ALX Oncology	N/A	-124.06%	-85.57%

Cullinan Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 82.86%. ALX Oncology has a consensus target price of $4.60, suggesting a potential upside of 139.58%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cullinan Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

ALX Oncology beats Cullinan Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and ALX Oncology (NASDAQ:ALXO) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Hyperliquid Strategies has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,018.37	-$16.01M	-$7.37	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

Hyperliquid Strategies presently has a consensus price target of $12.72, suggesting a potential upside of 80.38%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 139.58%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Hyperliquid Strategies' return on equity of -56.04% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
ALX Oncology	N/A	-124.06%	-85.57%

Hyperliquid Strategies has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

9.5% of Hyperliquid Strategies shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 8.5% of Hyperliquid Strategies shares are held by insiders. Comparatively, 21.0% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ALX Oncology had 1 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 1 mentions for ALX Oncology and 0 mentions for Hyperliquid Strategies. ALX Oncology's average media sentiment score of 1.94 beat Hyperliquid Strategies' score of 0.26 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperliquid Strategies	Neutral
ALX Oncology	Very Positive

Summary

ALX Oncology beats Hyperliquid Strategies on 8 of the 14 factors compared between the two stocks.

How does ALX Oncology compare to BioAge Labs?

ALX Oncology (NASDAQ:ALXO) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

BioAge Labs has higher revenue and earnings than ALX Oncology. BioAge Labs is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
BioAge Labs	$8.99M	110.36	-$80.61M	-$2.40	N/A

In the previous week, BioAge Labs had 4 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for BioAge Labs and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.94 beat BioAge Labs' score of 0.57 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BioAge Labs	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 139.58%. BioAge Labs has a consensus price target of $43.50, suggesting a potential upside of 94.89%. Given ALX Oncology's higher probable upside, analysts clearly believe ALX Oncology is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

98.0% of ALX Oncology shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by company insiders. Comparatively, 20.8% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ALX Oncology has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
BioAge Labs	-871.75%	-29.40%	-27.26%

ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Summary

BioAge Labs beats ALX Oncology on 8 of the 15 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$258.36M	$3.62B	$6.78B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.36%
P/E Ratio	-1.29	20.66	27.10	23.96
Price / Sales	N/A	300.74	573.91	112.12
Price / Cash	N/A	60.31	26.68	47.27
Price / Book	4.00	7.92	10.66	6.14
Net Income	-$101.69M	$23.81M	$3.60B	$331.74M
7 Day Performance	-2.54%	-1.27%	-1.51%	-1.72%
1 Month Performance	25.49%	2.56%	1.11%	-1.44%
1 Year Performance	279.00%	42.49%	23.77%	16.97%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	3.1286 of 5 stars	$1.92 -8.6%	$4.60 +139.6%	+314.5%	$258.36M	N/A	N/A	40
COLL Collegium Pharmaceutical	2.6157 of 5 stars	$34.82 -1.2%	$57.50 +65.1%	+15.6%	$1.14B	$780.57M	17.07	210	News Coverage
ORIC Oric Pharmaceuticals	2.0569 of 5 stars	$10.46 -3.6%	$19.27 +84.3%	-2.5%	$1.12B	N/A	N/A	80	Positive News
CGEM Cullinan Therapeutics	2.518 of 5 stars	$17.87 -1.4%	$32.00 +79.1%	+134.9%	$1.11B	N/A	N/A	30	News Coverage Gap Down
PURR Hyperliquid Strategies	1.9996 of 5 stars	$7.16 -5.2%	$12.72 +77.6%	N/A	$1.09B	$1M	N/A	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. COLL, ORIC, CGEM, PURR, and BIOA

How does ALX Oncology compare to Collegium Pharmaceutical?

Summary

How does ALX Oncology compare to Oric Pharmaceuticals?

Summary

How does ALX Oncology compare to Cullinan Therapeutics?

Summary

How does ALX Oncology compare to Hyperliquid Strategies?

Summary

How does ALX Oncology compare to BioAge Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. COLL, ORIC, CGEM, PURR, and BIOA

How does ALX Oncology compare to Collegium Pharmaceutical?

Does the media favor ALXO or COLL?

Which has more risk & volatility, ALXO or COLL?

Do analysts recommend ALXO or COLL?

Is ALXO or COLL more profitable?

Which has better valuation & earnings, ALXO or COLL?

Do insiders & institutionals believe in ALXO or COLL?

Summary

How does ALX Oncology compare to Oric Pharmaceuticals?

Which has more risk and volatility, ORIC or ALXO?

Which has higher earnings & valuation, ORIC or ALXO?

Does the media refer more to ORIC or ALXO?

Do institutionals & insiders believe in ORIC or ALXO?

Is ORIC or ALXO more profitable?

Do analysts rate ORIC or ALXO?

Summary

How does ALX Oncology compare to Cullinan Therapeutics?

Which has stronger earnings & valuation, CGEM or ALXO?

Does the media favor CGEM or ALXO?

Do insiders & institutionals hold more shares of CGEM or ALXO?

Is CGEM or ALXO more profitable?

Do analysts rate CGEM or ALXO?

Which has more risk and volatility, CGEM or ALXO?

Summary

How does ALX Oncology compare to Hyperliquid Strategies?

Which has preferable valuation & earnings, PURR or ALXO?

Do analysts prefer PURR or ALXO?

Is PURR or ALXO more profitable?

Which has more volatility & risk, PURR or ALXO?

Do institutionals and insiders hold more shares of PURR or ALXO?

Does the media favor PURR or ALXO?

Summary

How does ALX Oncology compare to BioAge Labs?

Which has higher valuation & earnings, ALXO or BIOA?

Does the media refer more to ALXO or BIOA?

Do analysts recommend ALXO or BIOA?

Do insiders & institutionals hold more shares of ALXO or BIOA?

Is ALXO or BIOA more profitable?

Which has more volatility & risk, ALXO or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools